Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (5): 391-396.doi: 10.35541/cjd.20210056
• Guidelines and Consensus • Previous Articles Next Articles
Committee on Allergic Diseases, China Dermatologist Association; Atopic Dermatitis Research Center, Chinese Society of Dermatology; Dermatology Branch of China International Exchange and Promotion Association for Medical and Healthcare
Received:
2021-01-20
Revised:
2021-03-09
Online:
2021-05-15
Published:
2021-04-29
Contact:
Hao Fei; Zhang Jianzhong; Jin Hongzhong
E-mail:haofei62@126.com;rmzjz@126.com;jinhongzhong@263.net
Committee on Allergic Diseases, China Dermatologist Association, Atopic Dermatitis Research Center, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotion Association for Medical and Healthcare. Expert consensus for management of itch in atopic dermatitis[J]. Chinese Journal of Dermatology, 2021, 54(5): 391-396.doi:10.35541/cjd.20210056
[1] | Elmariah SB. Adjunctive management of itch in atopic dermatitis[J]. Dermatol Clin, 2017,35(3):373⁃394. doi: 10.1016/j.det.2017. 02.011. |
[2] | Sidbury R, Kodama S. Atopic dermatitis guidelines: diagnosis, systemic therapy, and adjunctive care[J]. Clin Dermatol, 2018,36(5):648⁃652. doi: 10.1016/j.clindermatol.2018.05.008. |
[3] | 中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020,53(2):81⁃88. doi: 10.35541/cjd.20191000. |
[4] | El Hachem M, Di Mauro G, Rotunno R, et al. Pruritus in pediatric patients with atopic dermatitis: a multidisciplinary approach ⁃ summary document from an Italian expert group[J]. Ital J Pediatr, 2020,46(1):11. doi: 10.1186/s13052⁃020⁃0777⁃9. |
[5] | Murota H, Katayama I. Exacerbating factors of itch in atopic dermatitis[J]. Allergol Int, 2017,66(1):8⁃13. doi: 10.1016/j.alit.2016.10.005. |
[6] | Chamlin SL, Mattson CL, Frieden IJ, et al. The price of pruritus: sleep disturbance and cosleeping in atopic dermatitis[J]. Arch Pediatr Adolesc Med, 2005,159(8):745⁃750. doi: 10.1001/archpedi.159.8.745. |
[7] | Huet F, Faffa MS, Poizeau F, et al. Characteristics of pruritus in relation to self⁃assessed severity of atopic dermatitis[J]. Acta Derm Venereol, 2019,99(3):279⁃283. doi: 10.2340/00015555⁃3053. |
[8] | Fujii M. Current understanding of pathophysiological mechanisms of atopic dermatitis: interactions among skin barrier dysfunction, immune abnormalities and pruritus[J]. Biol Pharm Bull, 2020,43(1):12⁃19. doi: 10.1248/bpb.b19⁃00088. |
[9] | Dawn A, Papoiu AD, Chan YH, et al. Itch characteristics in atopic dermatitis: results of a web⁃based questionnaire[J]. Br J Dermatol, 2009,160(3):642⁃644. doi: 10.1111/j.1365⁃2133. 2008.08941.x. |
[10] | Darsow U, Scharein E, Simon D, et al. New aspects of itch pathophysiology: component analysis of atopic itch using the ′Eppendorf Itch Questionnaire′[J]. Int Arch Allergy Immunol, 2001,124(1⁃3):326⁃331. doi: 10.1159/000053748. |
[11] | Ständer S, Augustin M, Reich A, et al. Pruritus assessment in clinical trials: consensus recommendations from the International Forum for the Study of Itch (IFSI) special interest group scoring itch in clinical trials[J]. Acta Derm Venereol, 2013,93(5):509⁃514. doi: 10.2340/00015555⁃1620. |
[12] | Chrostowska⁃Plak D, Salomon J, Reich A, et al. Clinical aspects of itch in adult atopic dermatitis patients[J]. Acta Derm Venereol, 2009,89(4):379⁃383. doi: 10.2340/00015555⁃0676. |
[13] | 中国医师协会皮肤科分会变态反应性疾病专业委员会. 慢性瘙痒管理指南(2018版)[J]. 中华皮肤科杂志, 2018,51(7):481⁃485. doi: 10.3760/cma.j.issn.0412⁃4030.2018.07.001. |
[14] | Elman S, Hynan LS, Gabriel V, et al. The 5⁃D itch scale: a new measure of pruritus[J]. Br J Dermatol, 2010,162(3):587⁃593. doi: 10.1111/j.1365⁃2133.2009.09586.x. |
[15] | Micali G, Paternò V, Cannarella R, et al. Evidence⁃based treatment of atopic dermatitis with topical moisturizers[J]. G Ital Dermatol Venereol, 2018,153(3):396⁃402. doi: 10.23736/S0392⁃0488.18.05898⁃4. |
[16] | Pavlis J, Yosipovitch G. Management of itch in atopic dermatitis[J]. Am J Clin Dermatol, 2018,19(3):319⁃332. doi: 10.1007/s40257⁃017⁃0335⁃4. |
[17] | Senba E, Katanosaka K, Yajima H, et al. The immunosuppressant FK506 activates capsaicin⁃ and bradykinin⁃sensitive DRG neurons and cutaneous C⁃fibers[J]. Neurosci Res, 2004,50(3):257⁃262. doi: 10.1016/j.neures.2004.07.005. |
[18] | Pereira U, Boulais N, Lebonvallet N, et al. Mechanisms of the sensory effects of tacrolimus on the skin[J]. Br J Dermatol, 2010,163(1):70⁃77. doi: 10.1111/j.1365⁃2133.2010.09757.x. |
[19] | Sher LG, Chang J, Patel IB, et al. Relieving the pruritus of atopic dermatitis: a meta⁃analysis[J]. Acta Derm Venereol, 2012,92(5):455⁃461. doi: 10.2340/00015555⁃1360. |
[20] | Paller AS, Lebwohl M, Fleischer AB Jr, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies[J]. J Am Acad Dermatol, 2005,52(5):810⁃822. doi: 10.1016/j.jaad.2004.12.038. |
[21] | Roekevisch E, Spuls PI, Kuester D, et al. Efficacy and safety of systemic treatments for moderate⁃to⁃severe atopic dermatitis: a systematic review[J]. J Allergy Clin Immunol, 2014,133(2):429⁃438. doi: 10.1016/j.jaci.2013.07.049. |
[22] | Simon D, Bieber T. Systemic therapy for atopic dermatitis[J]. Allergy, 2014,69(1):46⁃55. doi: 10.1111/all.12339. |
[23] | Andersen HH, Elberling J, Sølvsten H, et al. Nonhistaminergic and mechanical itch sensitization in atopic dermatitis[J]. Pain, 2017,158(9):1780⁃1791. doi: 10.1097/j.pain.0000000000000980. |
[24] | Yamanaka K, Motomura E, Noro Y, et al. Olopatadine, a non⁃sedating H1 antihistamine, decreases the nocturnal scratching without affecting sleep quality in atopic dermatitis[J]. Exp Dermatol, 2015,24(3):227⁃229. doi: 10.1111/exd.12630. |
[25] | Henz BM, Metzenauer P, O′Keefe E, et al. Differential effects of new⁃generation H1⁃receptor antagonists in pruritic dermatoses[J]. Allergy, 1998,53(2):180⁃183. doi: 10.1111/j.1398⁃9995. 1998.tb03867.x. |
[26] | Matsuda KM, Sharma D, Schonfeld AR, et al. Gabapentin and pregabalin for the treatment of chronic pruritus[J]. J Am Acad Dermatol, 2016,75(3):619⁃625.e6. doi: 10.1016/j.jaad.2016.02. 1237. |
[27] | Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study[J]. J Am Acad Dermatol, 2004,50(6):889⁃891. doi: 10.1016/j.jaad.2004. 01.045. |
[28] | Malekzad F, Arbabi M, Mohtasham N, et al. Efficacy of oral naltrexone on pruritus in atopic eczema: a double⁃blind, placebo⁃controlled study[J]. J Eur Acad Dermatol Venereol, 2009,23(8):948⁃950. doi: 10.1111/j.1468⁃3083.2009.03129.x. |
[29] | Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus[J]. J Am Acad Dermatol, 2006,54(3):527⁃531. doi: 10.1016/j.jaad.2005.12.010. |
[30] | Simpson EL, Bieber T, Guttman⁃Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis[J]. N Engl J Med, 2016,375(24):2335⁃2348. doi: 10.1056/NEJMoa 1610020. |
[31] | Wollenberg A, Blauvelt A, Guttman⁃Yassky E, et al. Tralokinumab for moderate⁃to⁃severe atopic dermatitis: results from two 52⁃week, randomized, double⁃blind, multicentre, placebo⁃controlled phase III trials (ECZTRA 1 and ECZTRA 2)[J]. Br J Dermatol, 2020,doi: 10.1111/bjd.19574. |
[32] | Ruzicka T, Hanifin JM, Furue M, et al. Anti⁃interleukin⁃31 receptor a antibody for atopic dermatitis[J]. N Engl J Med, 2017,376(9):826⁃835. doi: 10.1056/NEJMoa1606490. |
[33] | Soeberdt M, Kilic A, Abels C. Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis[J]. Eur J Pharmacol, 2020,881:173242. doi: 10.1016/j.ejphar.2020.173242. |
[34] | Tom WL, Van Syoc M, Chanda S, et al. Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis: an open⁃label phase 2a study[J]. Pediatr Dermatol, 2016,33(2):150⁃159. doi: 10.1111/pde. 12780. |
[35] | Worm M, Thyssen J, Schliemann S, et al. The topical pan⁃JAK inhibitor delgocitinib cream demonstrates dose response in a 16⁃week phase 2b trial in chronic hand eczema.2020 EADV abstract. |
[36] | Nakagawa H, Nemoto O, Igarashi A, et al. Long⁃term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis[J]. J Dermatol, 2020,47(2):114⁃120. doi: 10.1111/1346⁃8138.15173. |
[37] | 中华医学会皮肤性病学分会儿童皮肤病学组. 中国儿童特应性皮炎诊疗共识(2017版)[J]. 中华皮肤科杂志, 2017,50(11):784⁃789. doi: 10.3760/cma.j.issn.0412⁃4030.2017.11.002. |
[1] | Guo Lan, Jin Hongzhong. Small-molecule/biological agents in the treatment of pruritus [J]. Chinese Journal of Dermatology, 2024, 57(5): 475-478. |
[2] | Chinese Society of Dermatology, China Dermatologist Association, Chinese Association of Integrative Medicine Board of Dermatovenereology. Expert consensus on the clinical application of chemical peeling in China (2024 public version) [J]. Chinese Journal of Dermatology, 2024, 0(5): 20230620-e20230620. |
[3] | Writing Committee Expert Group on “Treatment of Extramammary Paget′s Disease: a Chinese Expert Consensus Statement ()”. Treatment of extramammary Paget′s disease: a Chinese expert consensus statement (2024) [J]. Chinese Journal of Dermatology, 2024, 57(5): 400-408. |
[4] | China Dermatologist Association. Guidelines for the management of chronic pruritus (2024) [J]. Chinese Journal of Dermatology, 2024, 57(5): 387-399. |
[5] | Mycobacteriosis Research Group, China “Belt and Road” Dermatology Alliance, Division of Dermatology and STI Diagnosis, Chinese Association on Leprosy. Expert consensus on the clinical diagnosis and treatment of cutaneous tuberculosis in China (2024) [J]. Chinese Journal of Dermatology, 2024, 57(5): 426-434. |
[6] | China Dermatologist Association, Combination of Traditional and Western Medicine Dermatology. Diagnosis and treatment of erythrodermic psoriasis: a Chinese expert consensus statement (2024) [J]. Chinese Journal of Dermatology, 2024, 57(5): 409-417. |
[7] | Hospital for Skin Diseases, Chinese Academy of Medical Sciences, National Center for STD Control, Chinese Center for Disease Control and Prevention, Venereology Group, Chinese Society of Dermatology, Chinese Association Rehabilitation of Dermatology . Chinese expert consensus on the diagnosis and treatment of Mycoplasma genitalium infection (2024) [J]. Chinese Journal of Dermatology, 2024, 57(3): 201-208. |
[8] | China Dermatologist Association, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases. Expert consensus on the application and management of therapeutic drugs for atopic dermatitis (2024) [J]. Chinese Journal of Dermatology, 2024, 57(2): 97-108. |
[9] | Mycobacteriosis Research Group, China " Belt and Road " Dermatology Alliance, Division of Dermatology and STI Diagnosis, Chinese Association on Leprosy. Expert consensus on the diagnosis and treatment of cutaneous nontuberculous mycobacterial diseases in China (2024) [J]. Chinese Journal of Dermatology, 2024, 57(2): 109-118. |
[10] | STAR-Dermatology Professional Committee. Scientificity, transparency and applicability rankings of Chinese dermatological guidelines and consensus published in medical journals in 2022 [J]. Chinese Journal of Dermatology, 2024, 57(2): 141-146. |
[11] | Skin Cancer Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine, Melanoma Society of China Anti-Cancer Association. Expert consensus on human interferon α1b for the treatment of melanoma (2024) [J]. Chinese Journal of Dermatology, 2024, 57(1): 1-7. |
[12] | Chen Yaolong, Liu Hui, Yao Zhirong, Gao Xinghua. Strategies and suggestions for improving the quality of guidelines and consensus in the field of dermatology [J]. Chinese Journal of Dermatology, 2023, 56(9): 805-808. |
[13] | China Dermatologist Association. Guidance on application of moisturizers and emollients: an expert consensus (2023) [J]. Chinese Journal of Dermatology, 2023, 56(8): 711-717. |
[14] | Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China (2023)” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 56(6): 534-539. |
[15] | Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of chronic inducible urticaria in China (2023) [J]. Chinese Journal of Dermatology, 2023, 56(6): 479-488. |
|